These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37518350)

  • 1. Initial Triple Combination Therapy Including Intravenous Prostaglandin I
    Tamura Y; Kumamaru H; Nishimura S; Nakajima Y; Matsubara H; Taniguchi Y; Tsujino I; Shigeta A; Kinugawa K; Kimura K; Tatsumi K
    Int Heart J; 2023; 64(4):684-692. PubMed ID: 37518350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan.
    Tamura Y; Kumamaru H; Inami T; Matsubara H; Hirata KI; Tsujino I; Suda R; Miyata H; Nishimura S; Sigel B; Takano M; Tatsumi K;
    JACC Asia; 2022 Jun; 2(3):273-284. PubMed ID: 36338395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of pulmonary arterial hypertension with chronic hepatitis that resulted in hepatosplenomegaly after administration of prostaglandin I2.
    Goten C; Usui S; Hamaoka T; Harada T; Inoue O; Okada H; Takashima SI; Kato T; Murai H; Sakata K; Furusho H; Kawashiri MA; Takamura M
    J Cardiol Cases; 2020 May; 21(5):182-185. PubMed ID: 32373243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
    Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Living-donor liver transplantation for congenital biliary atresia with porto-pulmonary hypertension and moderate or severe pulmonary arterial hypertension: Kyoto University experience.
    Ogawa E; Hori T; Doi H; Segawa H; Uemoto S
    Clin Transplant; 2014 Sep; 28(9):1031-40. PubMed ID: 24986560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.
    Thomas IC; Glassner-Kolmin C; Gomberg-Maitland M
    Int J Cardiol; 2013 Oct; 168(4):4117-21. PubMed ID: 23890862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
    Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M; Piercy J; Pike J; Cerulli A
    Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk factors of early death after lung transplantation in patients with idiopathic pulmonary fibrosis complicated with pulmonary arterial hypertension].
    Hu C; Liu M; Yu H; Wang J; Li X; Yue B; Huang D; Hu C; Chen J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Feb; 35(2):124-129. PubMed ID: 36916370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP;
    J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.
    Akagi S; Nakamura K; Matsubara H; Kusano KF; Kataoka N; Oto T; Miyaji K; Miura A; Ogawa A; Yoshida M; Ueda-Ishibashi H; Yutani C; Ito H
    Int J Cardiol; 2013 May; 165(3):499-505. PubMed ID: 21955608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension.
    Sadeghi S; Granton JT; Akhavan P; Pasarikovski CR; Roos AM; Thenganatt J; Moric J; Johnson SR
    Respirology; 2015 Apr; 20(3):481-7. PubMed ID: 25583377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of pulmonary hypertension].
    Damps-Konstańska I; Konstański Z; Jassem E
    Wiad Lek; 2007; 60(11-12):545-9. PubMed ID: 18540180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Connective Tissue Growth Factor as a Biomarker of Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Adults.
    Liu W; Hua Y; Zheng D; Lv W; Zhang W; Chen Q; Huang R; Li X
    Circ J; 2023 Mar; 87(4):527-535. PubMed ID: 36843115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.